Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 28, 2015	Jul. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	0000031791
Current Fiscal Year End Date	--01-03
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 28, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		113,383,409
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

Condensed Consolidated Income Statements (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Product revenue	$ 388,718	$ 381,609	$ 748,031	$ 747,093
Service revenue	175,188	174,561	342,776	339,687
Total revenue	563,906	556,170	1,090,807	1,086,780
Cost of product revenue	201,675	201,649	386,284	390,933
Cost of service revenue	109,719	106,537	216,637	212,150
Total cost of revenue	311,394	308,186	602,921	603,083
Selling, general and administrative expenses	146,742	147,253	292,615	299,690
Research and development expenses	32,683	30,352	64,803	59,731
Restructuring and contract termination charges, net	4,956	742	4,956	2,877
Operating income from continuing operations	68,131	69,637	125,512	121,399
Interest and other expense, net	10,843	8,964	20,264	20,253
Income from continuing operations before income taxes	57,288	60,673	105,248	101,146
Provision for income taxes	8,292	8,670	15,941	14,192
Income from continuing operations	48,996	52,003	89,307	86,954
Gain (loss) from discontinued operations before income taxes	35	(2,084)	(2)	(3,114)
Loss on disposition of discontinued operations before income taxes	(10)	(302)	(23)	(374)
Provision for (benefit from) income taxes on discontinued operations and dispositions	47	(873)	(26)	(1,248)
(Loss) gain from discontinued operations and dispositions	(22)	(1,513)	1	(2,240)
Net income	$ 48,974	$ 50,490	$ 89,308	$ 84,714
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.43	$ 0.46	$ 0.79	$ 0.77
Gain (loss) on discontinued operations and dispositions (per share)	$ 0.00	$ (0.01)	$ 0.00	$ (0.02)
Net income (per share)	$ 0.43	$ 0.45	$ 0.79	$ 0.75
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.43	$ 0.46	$ 0.79	$ 0.76
Gain (loss) on discontinued operations and dispositions (per share)	$ 0.00	$ (0.01)	$ 0.00	$ (0.02)
Net income (per share)	$ 0.43	$ 0.44	$ 0.79	$ 0.74
Weighted average shares of common stock outstanding:
Basic (in shares)	113,018	112,788	112,829	112,671
Diluted (in shares)	113,833	113,971	113,636	113,874
Cash dividends per common share	$ 0.07	$ 0.07	$ 0.14	$ 0.14

Condensed Consolidated Statements of Comprehensive Income (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Net income	$ 48,974	$ 50,490	$ 89,308	$ 84,714
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments	12,271	2,706	(11,426)	3,340
Unrealized (losses) gains on securities, net of tax	(34)	2	(63)	(30)
Other comprehensive income (loss)	12,237	2,708	(11,489)	3,310
Comprehensive income	$ 61,211	$ 53,198	$ 77,819	$ 88,024

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 28, 2015	Dec. 28, 2014
Current assets:
Cash and cash equivalents	$ 192,170	$ 174,821
Accounts receivable, net	425,698	470,563
Inventories	304,754	285,457
Other current assets	147,706	137,710
Total current assets	1,070,328	1,068,551
Property, plant and equipment, net:
At cost	492,497	492,814
Accumulated depreciation	(326,180)	(316,620)
Property, plant and equipment, net	166,317	176,194
Marketable securities and investments	1,633	1,568
Intangible assets, net	454,251	490,265
Goodwill	2,275,898	2,284,077
Other assets, net	114,329	113,420
Total assets	4,082,756	4,134,075
Current liabilities:
Current portion of long-term debt	1,974	1,075
Accounts payable	170,677	173,953
Accrued expenses and other current liabilities	15,402	17,124
Accrued expenses and other current liabilities	384,182	403,021
Current liabilities of discontinued operations	2,109	2,137
Total current liabilities	574,344	597,310
Long-term debt	986,452	1,051,892
Long-term liabilities	401,056	442,771
Total liabilities	1,961,852	2,091,973
Commitments and contingencies (see Note 18)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 113,355,000 shares and 112,481,000 shares at June 28, 2015 and at December 28, 2014, respectively	113,355	112,481
Capital in excess of par value	110,239	94,276
Retained earnings	1,883,999	1,810,545
Accumulated other comprehensive income	13,311	24,800
Total stockholders’ equity	2,120,904	2,042,102
Total liabilities and stockholders’ equity	$ 4,082,756	$ 4,134,075

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 28, 2015	Dec. 28, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	113,355,000	112,481,000
Common stock, outstanding	113,355,000	112,481,000

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014
Operating activities:
Net income	$ 89,308	$ 84,714
Less: (gain) loss from discontinued operations and dispositions, net of income taxes	(1)	2,240
Income from continuing operations	89,307	86,954
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	4,956	2,877
Depreciation and amortization	56,593	57,907
Stock-based compensation	8,193	9,319
Amortization of deferred debt financing costs and accretion of discount	677	662
Amortization of acquired inventory revaluation	6,467	0
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	30,843	23,434
Inventories	(33,327)	(15,737)
Accounts payable	(1,541)	(11,867)
Accrued expenses and other	(61,007)	(30,979)
Net cash provided by operating activities of continuing operations	101,161	122,570
Net cash used in operating activities of discontinued operations	(27)	(464)
Net cash provided by operating activities	101,134	122,106
Investing activities:
Capital expenditures	(10,099)	(14,447)
Proceeds from surrender of life insurance policies	0	425
Changes in restricted cash balances	(59)	0
Activity related to acquisitions and investments, net of cash and cash equivalents acquired	(18,735)	(350)
Net cash used in investing activities of continuing operations	(28,775)	(14,372)
Net cash used in investing activities of discontinued operations	0	(213)
Net cash used in investing activities	(28,775)	(14,585)
Financing activities:
Payments on revolving credit facility	(249,000)	(232,000)
Proceeds from revolving credit facility	184,000	193,000
Payments of debt financing costs	0	(1,845)
Settlement of hedges	23,468	0
Net proceeds from (payments on) other credit facilities	344	(507)
Proceeds from issuance of common stock under stock plans	12,669	19,454
Purchases of common stock	(4,095)	(38,976)
Dividends paid	(15,799)	(15,809)
Net cash used in financing activities	(48,413)	(76,683)
Effect of exchange rate changes on cash and cash equivalents	(6,597)	1,178
Net increase in cash and cash equivalents	17,349	32,016
Cash and cash equivalents at beginning of period	174,821	173,242
Cash and cash equivalents at end of period	$ 192,170	$ 205,258

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 28, 2015
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 28, 2014, filed with the SEC (the “2014 Form 10-K”). The balance sheet amounts at December 28, 2014 in this report were derived from the Company’s audited 2014 consolidated financial statements included in the 2014 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June 28, 2015 and June 29, 2014, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from June 28, 2015 through the date of the issuance of these condensed consolidated financial statements and has determined that other than the events the Company has disclosed within the footnotes to the financial statements, no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure. The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. The fiscal year ending January 3, 2016 ("fiscal year 2015") will include 53 weeks and the extra week will be included in the third quarter. The fiscal year ended December 28, 2014 ("fiscal year 2014") included 52 weeks. Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The initial provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. Subsequent to the issuance of the standard, the Financial Accounting Standards Board decided to defer the effective date for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows. In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-04, Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. Under this new guidance, an entity with a fiscal year-end that does not coincide with a calendar month-end (for example an entity that has a 52/53 week fiscal year) has the ability, as a practical expedient, to measure its defined benefit retirement obligations and related plan assets as of the month-end that is closest to its fiscal year end. During the second quarter of fiscal year 2015, the Company early adopted the new guidance. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows.

Business Combinations

6 Months Ended

Jun. 28, 2015

Business Combinations [Abstract]

Business Combinations

Acquisitions in fiscal year 2015

During the first six months of fiscal year 2015, the Company completed the acquisition of three businesses for total consideration of $19.0 million in cash. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired. As a result of these acquisitions, the Company recorded goodwill of $13.7 million and intangible assets of $6.1 million. The Company has reported the operations for these acquisitions within the results of the Company's Human Health and Environmental Health segments from the acquisition dates. As of June 28, 2015, the purchase accounting allocations related to these acquisitions were preliminary.

Acquisitions in fiscal year 2014

Acquisition of Perten Instruments Group AB. In December 2014, the Company acquired all of the outstanding stock of Perten Instruments Group AB ("Perten"). Perten is a provider of analytical instruments and services for quality control of food, grain, flour and feed. The Company expects this acquisition to enhance its industrial, environmental and safety business by expanding the Company's product offerings to the academic and industrial end markets. The Company paid the shareholders of Perten $269.9 million in cash for the stock of Perten. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Environmental Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, customer relationships and trade names, acquired as part of this acquisition had weighted average amortization periods of approximately 5 to 10 years.

Other acquisitions in fiscal year 2014. In addition to the Perten acquisition, the Company completed the acquisition of two businesses in fiscal year 2014 for total consideration of $18.0 million in cash and $4.3 million of assumed debt. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates. As of June 28, 2015, the purchase accounting allocations related to acquisitions completed during fiscal year 2014 were preliminary.

The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:



	Perten			2014 Other
	(Preliminary)
	(In thousands)
Fair value of business combination:
Cash payments	$	269,937		$	17,898
Working capital and other adjustments	—			151
Less: cash acquired	(16,732		)	(124		)
Total	$	253,205		$	17,925
Identifiable assets acquired and liabilities assumed:
Current assets	$	32,805		$	1,965
Property, plant and equipment	1,485			125
Other assets	—			364
Identifiable intangible assets:
Core technology	16,000			1,705
Trade names	7,000			—
Customer relationships	87,000			6,800
IPR&D	—			1,266
Goodwill	164,164			15,981
Deferred taxes	(31,454		)	(3,072		)
Deferred revenue	—			(589		)
Liabilities assumed	(16,195		)	(2,333		)
Debt assumed	(7,600		)	(4,287		)
Total	$	253,205		$	17,925

The preliminary allocations of the purchase prices for acquisitions completed in fiscal years 2015 and 2014 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. Adjustments to the preliminary allocation of the purchase prices during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocation of the purchase prices made during the measurement periods would be as if the adjustments had been completed on the acquisition dates. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement periods are included in current period earnings.

Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period.

The Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $32.5 million as of June 28, 2015. As of June 28, 2015, the Company had recorded contingent consideration obligations, which were assumed as part of the Perten acquisition, with an estimated fair value of $0.5 million. The earnout period for acquisitions with open contingency periods does not exceed three years from the respective acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional consideration which would be expensed.

Total transaction costs related to acquisition activities for the three and six months ended June 28, 2015 were $0.2 million and $0.4 million, respectively. Total transaction costs related to acquisition activities for the three and six months ended June 29, 2014 were $0.1 million and $0.2 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Discontinued Operations

6 Months Ended

Jun. 28, 2015

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of June 28, 2015 and December 28, 2014.

In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which had been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.3 million net pre-tax loss related to the disposal of fixed assets and inventory for the three months ended June 29, 2014.

During the first six months of each of fiscal years 2015 and 2014, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized net pre-tax losses of $0.01 million and $0.02 million for the three and six months ended June 28, 2015, respectively. The Company also recognized net pre-tax losses of $0.05 million and $0.1 million related to other discontinued operations for the three and six months ended June 29, 2014, respectively. These losses were recognized as a loss on disposition of discontinued operations.

Summary pre-tax operating results of the discontinued operations, which include the periods prior to disposition and a $1.0 million pre-tax restructuring charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during the second quarter of fiscal year 2014, were as follows:



	Three Months Ended					Six Months Ended
	June 28, 2015		June 29, 2014			June 28, 2015			June 29, 2014
	(In thousands)
Sales	$	63	$	426		$	83		$	1,720
Costs and expenses	28		2,510			85			4,834
Gain (loss) from discontinued operations before income taxes	$	35	$	(2,084	)	$	(2	)	$	(3,114	)

The Company recorded a tax provision of $0.05 million and a tax benefit of $0.03 million on discontinued operations and dispositions for the three and six months ended June 28, 2015, respectively. The Company recorded tax benefits of $0.9 million and $1.2 million on discontinued operations and dispositions for the three and six months ended June 29, 2014, respectively.

Restructuring and Lease Charges, Net

6 Months Ended

Jun. 28, 2015

Restructuring and Related Activities [Abstract]

Restructuring and Lease Charges, Net

Restructuring and Contract Termination Charges, Net

The Company's management has approved a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.

The Company implemented restructuring plans in the second quarter of fiscal year 2015 and the third quarter of fiscal year 2014 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q2 2015 Plan" and the "Q3 2014 Plan", respectively). The Company implemented restructuring plans in the second and first quarters of fiscal year 2014 consisting of workforce reductions principally intended to focus resources on higher growth end markets (the "Q2 2014 Plan" and the "Q1 2014 Plan", respectively). Details of the plans initiated in previous years (“Previous Plans”) are discussed more fully in Note 4 to the audited consolidated financial statements in the 2014 Form 10-K. The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company.

The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during the six months ended June 28, 2015 and fiscal year 2014:



		Initial Restructuring or Contract Termination Charges				Total		Date or Expected Date Payments Substantially Completed by
	Headcount Reduction	Human Health		Environmental Health		Total		Date or Expected Date Payments Substantially Completed by
	(In thousands, except headcount data)
Q2 2015 Plan	102	$	1,850	$	4,160	$	6,010	Q2 FY2016
2015 Contract Termination Charges	—	—		25		25		Q4 FY2015

Q3 2014 Plan	152	7,126		5,925		13,051		Q3 FY2015
Q2 2014 Plan	22	545		190		735		Q2 FY2015
Q1 2014 Plan	17	370		197		567		Q4 FY2014
2014 Contract Termination Charges	—	—		1,545		1,545		Q4 FY2015

The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022.

At June 28, 2015, the Company had $20.8 million recorded for accrued restructuring and contract termination charges, of which $15.4 million was recorded in short-term accrued restructuring and contract termination charges and $5.4 million was recorded in long-term liabilities. At December 28, 2014, the Company had $23.8 million recorded for accrued restructuring and contract termination charges, of which $17.1 million was recorded in short-accrued restructuring and $6.7 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination, during the six months ended June 28, 2015:



	Balance at December 28, 2014		2015 Charges		2015 Changes in Estimates, Net			2015 Amounts Paid			Balance at June 28, 2015
	(In thousands)
Severance:
Q2 2015 Plan	$	—	$	6,010	$	—		$	(600	)	$	5,410
Q3 2014 Plan	10,059		—		—			(5,050		)	5,009
Q2 2014 Plan⁽¹⁾	251		—		(179		)	(8		)	64
Q1 2014 Plan⁽²⁾	92		—		(92		)	—			—
Previous Plans⁽³⁾	13,124		—		(808		)	(2,199		)	10,117
Restructuring	23,526		6,010		(1,079		)	(7,857		)	20,600
Contract Termination	304		25		—			(141		)	188
Total Restructuring and Contract Termination	$	23,830	$	6,035	$	(1,079	)	$	(7,998	)	$	20,788


⁽¹⁾	During the six months ended June 28, 2015, the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Human Health and Environmental Health segments related to lower than expected costs associated with workforce reductions for the Q2 2014 Plan.


⁽²⁾	During the six months ended June 28, 2015, the Company recognized a pre-tax restructuring reversal of $0.1 million in the Human Health segment related to lower than expected costs associated with workforce reductions for the Q1 2014 Plan.

⁽³⁾

During the six months ended June 28, 2015, the Company recognized a net additional pre-tax restructuring charge of $0.2 million in the Human Health segment primarily related to higher than expected costs associated with the closure of the excess facility space and a pre-tax restructuring reversal of $1.0 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Previous Plans.

Income Taxes	6 Months Ended
Income Taxes	Jun. 28, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. At June 28, 2015, the Company had gross tax effected unrecognized tax benefits of $30.1 million, of which $26.3 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $5.4 million of its uncertain tax positions at June 28, 2015, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2007 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. During the first six months of fiscal years 2015 and 2014, the Company recorded net discrete income tax benefits of $2.8 million and $4.0 million, respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters.

Debt	6 Months Ended
Debt	Jun. 28, 2015
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The Company's senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. As of June 28, 2015, undrawn letters of credit in the aggregate amount of $12.2 million were treated as issued and outstanding under the senior unsecured revolving credit facility. As of June 28, 2015, the Company had $236.8 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At June 28, 2015, borrowings under the senior unsecured revolving credit facility were accruing interest primarily based on the Eurocurrency rate. The Eurocurrency margin as of June 28, 2015 was 108 basis points. The weighted average Eurocurrency interest rate as of June 28, 2015 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%. At June 28, 2015 and December 28, 2014, the Company had $451.0 million and $516.0 million, respectively, of borrowings in U.S. dollars outstanding under the senior unsecured revolving credit facility. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the credit agreement for the Company's previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of June 28, 2015, the 2021 Notes had an aggregate carrying value of $497.8 million, net of $2.2 million of unamortized original issue discount. As of December 28, 2014, the 2021 Notes had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At June 28, 2015, the Company had $38.7 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $37.6 million was recorded as long-term debt. At December 28, 2014, the Company had $39.3 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.2 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. Other Short-term Obligations. At June 28, 2015, the Company had $0.9 million of borrowings under other short-term obligation arrangements, which were settled during the third quarter of fiscal year 2015.

Earnings Per Share

6 Months Ended

Jun. 28, 2015

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:



	Three Months Ended		Six Months Ended
	June 28, 2015	June 29, 2014	June 28, 2015	June 29, 2014
	(In thousands)
Number of common shares—basic	113,018	112,788	112,829	112,671
Effect of dilutive securities:
Stock options	639	970	659	1,010
Restricted stock awards	176	213	148	193
Number of common shares—diluted	113,833	113,971	113,636	113,874
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	493	499	713	479

Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

6 Months Ended

Jun. 28, 2015

Segment Reporting [Abstract]

Industry Segment Information

The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2014 Form 10-K.

The Company realigned its organization at the beginning of fiscal year 2015 to enable the Company to both deliver complete solutions targeted towards certain end markets and develop value-added applications and solutions to foster further expansion of those markets. OneSource, the multivendor service offering business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. The results reported for the three and six months ended June 28, 2015 reflect this new alignment of the Company's operating segments. Financial information in this report relating to the three and six months ended June 29, 2014 and the fiscal year ended 2014 have been retrospectively adjusted to reflect the changes to the operating segments. The principal products and services of the Company's two operating segments are:


•	Human Health. Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.


•	Environmental Health. Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.

The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.

Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below:



	Three Months Ended						Six Months Ended
	June 28, 2015			June 29, 2014			June 28, 2015			June 29, 2014
	(In thousands)
Human Health
Product revenue	$	242,506		$	245,108		$	473,654		$	484,137
Service revenue	98,982			97,435			193,887			188,439
Total revenue	341,488			342,543			667,541			672,576
Operating income from continuing operations	60,531			57,908			116,413			101,890
Environmental Health
Product revenue	146,212			136,501			274,377			262,956
Service revenue	76,206			77,126			148,889			151,248
Total revenue	222,418			213,627			423,266			414,204
Operating income from continuing operations	19,422			25,578			30,768			47,185
Corporate
Operating loss from continuing operations⁽¹⁾	(11,822		)	(13,849		)	(21,669		)	(27,676		)
Continuing Operations
Product revenue	388,718			381,609			748,031			747,093
Service revenue	175,188			174,561			342,776			339,687
Total revenue	563,906			556,170			1,090,807			1,086,780
Operating income from continuing operations	68,131			69,637			125,512			121,399
Interest and other expense, net (see Note 5)	10,843			8,964			20,264			20,253
Income from continuing operations before income taxes	$	57,288		$	60,673		$	105,248		$	101,146

____________________________

⁽¹⁾

In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded in the second quarter of fiscal year 2014. In addition, the Company incurred $0.1 million and $3.4 million of expenses in preparation for the trial during the three and six months ended June 29, 2014, respectively.

Stockholders' Equity

6 Months Ended

Jun. 28, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders’ Equity

Comprehensive Income:

The components of accumulated other comprehensive income consisted of the following:



	June 28, 2015			December 28, 2014
	(In thousands)
Foreign currency translation adjustments	$	11,906		$	23,332
Unrecognized prior service costs, net of income taxes	1,575			1,575
Unrealized net losses on securities, net of income taxes	(170		)	(107		)
Accumulated other comprehensive income	$	13,311		$	24,800

Stock Repurchases:

On October 23, 2014, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 23, 2016 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the six months ended June 28, 2015, the Company did not repurchase shares of common stock in the open market, under the Repurchase Program. As of June 28, 2015, 7.4 million shares remained available for repurchase under the Repurchase Program.

In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the six months ended June 28, 2015, the Company repurchased 88,456 shares of common stock for this purpose at an aggregate cost of $4.1 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.

Dividends:

The Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quarters of fiscal year 2015 and in each quarter of fiscal year 2014. At June 28, 2015, the Company has accrued $7.9 million for dividends declared on April 27, 2015 for the second quarter of fiscal year 2015, payable in August 2015. On July 22, 2015, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2015 that will be payable in November 2015. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock Plans

6 Months Ended

Jun. 28, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Plans

In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued.

The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and six months ended June 28, 2015 and June 29, 2014:



	Three Months Ended				Six Months Ended
	June 28, 2015		June 29, 2014		June 28, 2015		June 29, 2014
	(In thousands)
Cost of product and service revenue	$	392	$	337	$	640	$	671
Research and development expenses	141		220		300		360
Selling, general and administrative expenses	3,673		4,246		7,253		8,288
Total stock-based compensation expense	$	4,206	$	4,803	$	8,193	$	9,319

The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.4 million and $2.7 million for the three and six months ended June 28, 2015, respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.8 million and $3.5 million for the three and six months ended June 29, 2014, respectively. Stock-based compensation costs capitalized as part of inventory were $0.3 million and $0.4 million as of June 28, 2015 and June 29, 2014, respectively.

Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:



	Three and Six Months Ended
	June 28, 2015		June 29, 2014
Risk-free interest rate	1.3	%	1.5	%
Expected dividend yield	0.6	%	0.7	%
Expected term	5 years		5 years
Expected stock volatility	26.5	%	30.9	%

The following table summarizes stock option activity for the six months ended June 28, 2015:



	Number of Shares		Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term	Total Intrinsic Value
	(In thousands)				(In years)	(In millions)
Outstanding at December 28, 2014	2,828		$	26.11
Granted	484		46.22
Exercised	(728	)	17.39
Canceled	(3	)	22.49
Forfeited	(78	)	30.63
Outstanding at June 28, 2015	2,503		$	32.40	4.1	$	49.3
Exercisable at June 28, 2015	1,619		$	26.33	3.0	$	41.7
Vested and expected to vest in the future	2,435		$	32.14	4.0	$	48.6

The Company did not grant any options during the three months ended June 28, 2015. The weighted-average per-share grant-date fair value of options granted during the six months ended June 28, 2015 was $10.99. The weighted-average per-share grant-date fair value of options granted during the three and six months ended June 29, 2014 was $11.80 and $11.84, respectively. The total intrinsic value of options exercised during the three and six months ended June 28, 2015 was $4.3 million and $21.9 million, respectively. The total intrinsic value of options exercised during the three and six months ended June 29, 2014 was $11.1 million and $17.6 million, respectively. Cash received from option exercises for the six months ended June 28, 2015 and June 29, 2014 was $12.7 million and $19.5 million, respectively.

The total compensation expense recognized related to the Company’s outstanding options was $1.1 million and $1.9 million for the three and six months ended June 28, 2015, respectively, and $1.4 million and $2.9 million for the three and six months ended June 29, 2014, respectively.

There was $8.1 million of total unrecognized compensation cost related to nonvested stock options granted as of June 28, 2015. This cost is expected to be recognized over a weighted-average period of 2.1 years and will be adjusted for any future changes in estimated forfeitures.

Restricted Stock Awards: The following table summarizes restricted stock award activity for the six months ended June 28, 2015:



	Number of Shares		Weighted- Average Grant- Date Fair Value
	(In thousands)
Nonvested at December 28, 2014	558		$	35.51
Granted	220		46.59
Vested	(229	)	30.38
Forfeited	(25	)	40.02
Nonvested at June 28, 2015	524		$	42.18

The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended June 28, 2015 was $51.13 and $46.59, respectively. The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended June 29, 2014 was $43.19 and $42.61, respectively. The fair value of restricted stock awards vested during the three and six months ended June 28, 2015 was $0.3 million and $7.0 million, respectively. The fair value of restricted stock awards vested during the three and six months ended June 29, 2014 was $0.2 million and $7.0 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $2.3 million and $4.3 million for the three and six months ended June 28, 2015, respectively, and $1.9 million and $3.9 million for the three and six months ended June 29, 2014, respectively.

As of June 28, 2015, there was $15.0 million of total unrecognized compensation cost related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.7 years.

Performance Units: The Company granted 66,509 and 79,463 performance units during the six months ended June 28, 2015 and June 29, 2014, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the six months ended June 28, 2015 and June 29, 2014 was $46.83 and $42.84, respectively. During the six months ended June 28, 2015, 8,860 performance units were forfeited. During the six months ended June 29, 2014, no performance units were forfeited. The total compensation expense recognized related to performance units was $0.1 million and $1.2 million for the three and six months ended June 28, 2015, respectively, and expenses of $0.7 million and $1.7 million for the three and six months ended June 29, 2014, respectively. As of June 28, 2015, there were 201,415 performance units outstanding and subject to forfeiture, with a corresponding liability of $3.3 million recorded in accrued expenses and other current liabilities.

Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 1,953 shares and 2,373 shares to each non-employee member of the Board during the six months ended June 28, 2015 and June 29, 2014, respectively. The Company also granted 544 shares to a new non-employee member of the Board during the three months ended March 29, 2015. The weighted-average per-share grant-date fair value of the stock awards granted during the six months ended June 28, 2015 and June 29, 2014 was $51.01 and $42.14, respectively. The total compensation expense recognized related to these stock awards was $0.7 million for each of the six months ended June 28, 2015 and June 29, 2014.

Employee Stock Purchase Plan: During the six months ended June 28, 2015, the Company issued 29,565 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $41.54 per share. During the six months ended June 29, 2014, the Company issued 31,854 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $39.17 per share. At June 28, 2015, an aggregate of 1.0 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill and Intangible Assets, Net

6 Months Ended

Jun. 28, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.

The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2015, its annual impairment date for fiscal year 2015. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20.0% for each reporting unit. The long-term terminal growth rates for the Company’s reporting units ranged from 4.0% to 6.5% for the fiscal year 2015 impairment analysis. The range for the discount rates for the reporting units was 9.5% to 12.5%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.

Subsequent to the 2015 annual impairment test, the Company realigned its organization, as discussed in Note 10. While the realignment did not have a significant impact on the fair values of the reporting units as discussed above, the realignment did result in a change in the composition of the Company's reportable segments. OneSource, the multivendor service offering business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. As a result of the new alignment, the Company reallocated goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the business. During the second quarter of 2015, the Company updated its preliminary analysis and the realignment resulted in $41.2 million of goodwill being reallocated from the Environmental Health segment into the Human Health segment as of December 28, 2014.

The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach.

The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2015, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first six months of fiscal year 2015.

The changes in the carrying amount of goodwill for the period ended June 28, 2015 from December 28, 2014 were as follows:



	Human Health			Environmental Health			Consolidated
	(In thousands)
Balance at December 28, 2014	$	1,662,755		$	621,322		$	2,284,077
Foreign currency translation	(15,453		)	(6,483		)	(21,936		)
Acquisitions and other	33			13,724			13,757
Balance at June 28, 2015	$	1,647,335		$	628,563		$	2,275,898

Identifiable intangible asset balances at June 28, 2015 and December 28, 2014 by category were as follows:



	June 28, 2015			December 28, 2014
	(In thousands)
Patents	$	39,923		$	39,953
Less: Accumulated amortization	(28,484		)	(27,200		)
Net patents	11,439			12,753
Trade names and trademarks	40,223			40,069
Less: Accumulated amortization	(18,852		)	(16,936		)
Net trade names and trademarks	21,371			23,133
Licenses	59,441			59,631
Less: Accumulated amortization	(43,623		)	(41,792		)
Net licenses	15,818			17,839
Core technology	299,785			298,491
Less: Accumulated amortization	(199,087		)	(184,697		)
Net core technology	100,698			113,794
Customer relationships	403,312			402,185
Less: Accumulated amortization	(175,018		)	(156,994		)
Net customer relationships	228,294			245,191
IPR&D	9,660			10,103
Less: Accumulated amortization	(3,613		)	(3,132		)
Net IPR&D	6,047			6,971
Net amortizable intangible assets	383,667			419,681
Non-amortizing intangible assets:
Trade names and trademarks	70,584			70,584
Total	$	454,251		$	490,265

Total amortization expense related to definite-lived intangible assets was $19.9 million and $39.7 million for the three and six months ended June 28, 2015, respectively, and $20.6 million and $41.3 million for the three and six months June 29, 2014, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $40.3 million for the remainder of fiscal year 2015, $70.7 million for fiscal year 2016, $60.9 million for fiscal year 2017, $49.9 million for fiscal year 2018, and $38.1 million for fiscal year 2019.

Warranty Reserves

6 Months Ended

Jun. 28, 2015

Product Warranties Disclosures [Abstract]

Warranty Reserves

The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets.

A summary of warranty reserve activity for the three and six months ended June 28, 2015 and June 29, 2014 is as follows:



	Three Months Ended						Six Months Ended
	June 28, 2015			June 29, 2014			June 28, 2015			June 29, 2014
	(In thousands)
Balance at beginning of period	$	10,871		$	10,357		$	10,783		$	10,534
Provision charged to income	4,330			4,332			8,488			8,409
Payments	(3,984		)	(4,388		)	(7,746		)	(8,355		)
Adjustments to previously provided warranties, net	(550		)	471			(471		)	174
Foreign currency translation and acquisitions	143			14			(244		)	24
Balance at end of period	$	10,810		$	10,786		$	10,810		$	10,786